论文部分内容阅读
目的观察口服替加氟节拍化疗配合放疗治疗晚期非小细胞肺癌的有效性和安全性。方法56例非小细胞肺癌(NSCLC,ⅢB期46例,Ⅳ期10例)中初治32例,复治24例。男38例,女18例。年龄46～78岁。服用替加氟50 mg,tid,持续服用至放疗结束后6个月或病情进展或毒性不能耐受为止。根据WHO标准评价疗效和毒性。结果全组56例患者均可评价,获CR 8例,PR 34例,SD 8例,PD 6例,有效率75.0%。中位无进展生存时间(TTP)为11.8个月,中位生存期(MST)为18.3个月。Karnofsky评分治疗前平均74.6分,治疗后平均为86.7分。1,2,3年生存率分别为75.0%、29.1%和11.7%。主要毒副反应为放射性食管炎、乏力、骨髓抑制、恶心和食欲不振,但均较轻微。结论口服替加氟节拍化疗配合放疗治疗晚期非小细胞肺癌,能延缓病情发展,提高患者生活质量,毒副作用轻微,费用低廉,易为患者接受。
Objective To observe the efficacy and safety of oral tegafur cardioplegia combined with radiotherapy in the treatment of advanced non-small cell lung cancer. Methods 56 cases of non-small cell lung cancer (NSCLC, Ⅲ B 46 cases, Ⅳ 10 cases) initial treatment of 32 cases, 24 cases of retreatment. 38 males and 18 females. Age 46 ~ 78 years old. Take tegafur 50 mg, tid, continued to take to 6 months after the end of radiotherapy or progression of the disease or toxicity can not tolerate so far. According to the WHO standard evaluation of efficacy and toxicity. Results All 56 patients were evaluable. Among them, 8 were CR, 34 were PR, 8 were SD, and 6 were PD. The effective rate was 75.0%. The median progression-free survival time (TTP) was 11.8 months and the median survival time (MST) was 18.3 months. Karnofsky score before treatment an average of 74.6 points, an average of 86.7 points after treatment. The 1, 2, 3 year survival rates were 75.0%, 29.1% and 11.7%, respectively. The main side effects of radiation esophagitis, fatigue, myelosuppression, nausea and loss of appetite, but were minor. Conclusion TEG chemotherapy with oral tegafur in combination with radiotherapy for advanced non-small cell lung cancer can delay the progression of the disease and improve the quality of life of patients with mild side effects, low cost and easy for patients to accept.